A Phase I/II study Evaluating the Dosing Safety Efficacy and Biological Activity of Intraperitoneal GEN-1 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer) Administered in Combination with Neoadjuvant Chemotherapy (NACT) in Patients Newly Diagnosed with Advanced Epithelial Ovarian Fallopian Tube or Primary Peritoneal Cancer
Brief description of study
You are being asked to take part in this study because you have epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer and you have elected to receive chemotherapy and surgery to treat your disease. This study utilizes a novel GEN-1 (IL-12 Plasmid) with neoadjuvant chemotherapy in newly diagnosed patients with advanced ovarian, fallopian tube or primary peritoneal cancer.
Clinical Study Identifier: s19-00063
ClinicalTrials.gov Identifier: NCT03393884
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
